At a glance
ClinicalIndex Comparison RecordN/ACompleted· 216 enrolled
Drug / intervention
RD-X19 +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Randomized, Sham Controlled Dose Finding Study of the RD-X19 Treatment Device in Individuals With Mild to Moderate COVID-19
In Brief
A clinical study evaluating RD-X19 and Sham for COVID19. Completed, enrolled 216 participants across 9 sites.
Detailed Summary
This is a randomized, sham controlled, dose finding study of the EmitBio RD-X19 device in individuals with symptomatic COVID-19 in the outpatient setting.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID19
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20222023202420252026
Enrollment StartJun 2021
First PostedJul 2021
Primary CompletionJan 2022
Study CompletionFeb 2022
TodayJul 2026
First PostedJul 19, 2021
Enrollment StartJun 17, 2021
Primary CompletionJan 5, 2022
Study CompletionFeb 23, 2022
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 5.0 years ago
Interventions
RD-X19device
Investigational device that uses safe electromagnetic energy to target the oropharynx.
Shamdevice
Investigational device that uses safe electromagnetic energy to target the oropharynx but at energy levels with a lower inactivation potential against SARS-CoV-2 in vitro..